9.28 USD
▲+0.24+15.14%
盘后 8.13 +0.88%
2026-08-03
市值
$575.21M
市盈率
—
EPS
-4.25
股息率
—
52 周区间
3.76 – 9.12
成交量
3.63M
Beta
0.56
目标价
35.29
52W 低 3.7652W 高 9.12
价格走势
公司简介
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central ne...